( )

REFERENCES

1.Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States  adults 1999-2004. Hypertension 2007; 49 (1): 69-75 

2.Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep. 2002;4: 424-433.

3. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:2101-2107.

4. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: A meta-analysis. Med Care. 2002;40:794-811.

5. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: A critical factor For blood pressure control.
EurJ Cardiovasc Prey Rehabil. 2005;12:243-249.

6. Gurnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. AmJ Hypertens. 2006;19:1190-1196.

7. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530..

8. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive  agents with placebo. The Department of Veterans Affairs  Cooperative Study Group on Antihypertensive Agents. N Engl  J Med 1993; 328 (13): 914-21

9. Major outcomes in high-risk hypertensive patients randomized  to angiotensin-converting enzyme inhibitor or calcium channel   vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97

10. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report  of the Joint National Committee on Prevention, Detection,  Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72

11, Chrysant SG. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998; 7 (4): 370-6

12. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713-9

13. Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993; 15 (6): 1299-313

14. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156 (17): 1969-78

15. Frishman WH. Results of hypertension treatment with low-dose combinations of a beta-adrenergic blocker and a diuretic. Am J Hypertens 1997; 10 (3): 17S-23S

16. Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992; 6 Suppl. 2: S19-21

17. Neutel JM, Black HR, Weber MA. Combination therapy with diuretics: an evolution of understanding. Am J Med 1996; 101 (3A): 61S-70S

18.Guidelines Committee 2003. European Society of Hypertension–European Society of Cardiology Guidelines for the management of arterial hypertension.
J Hypertens 2003; 21:1011–1053.

19.  National Kidney Foundation. K/DOQI Clinical Practice Guidelines on hypertension and antihypertensive agents in chronic kidney disease. Kidney Disease Outcomes Quality Initiative (K/DOQI) Am J Kidney Dis 2004; 43 (Suppl 1):S1–S290.

20.  American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007; 30 (Suppl 1):S4–S41.

21. Nash DT. Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. South Med J 2007; 100:386–392.

22. Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2007; 22:266–274.

23. Weir MR, Neutel JM, Bhaumik A, et al. The efficacy and safety of initial use of irbesartan/HCTZ fixed dose combination in hypertensive patients with and
without high cardiovascular risk. J Clin Hypertens 2007; 9 (12 Suppl):23–30

24. Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol  1987; 23 Suppl. 1: 43-50S

25. Brown CL, Backhouse CI, Grippat JC, et al. The effect of   perindopril and hydrochlorothiazide alone and in combination   on blood pressure and on the renin-angiotensin system in   hypertensive subjects. Eur J Clin Pharmacol 1990; 39 (4):  327-32 

26. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril- hydrochlorothiazide combination: a large multicenter  study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med, 1994; 154 (7): 737-43

27. Holland OB, von Kuhnert L, Campbell WB, et al. Synergistic  effect of captopril with hydrochlorothiazide for the treatment   of low-renin hypertensive black patients. Hypertension 1983; 5 (2): 235-9

28. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive   therapy on serum lipids. Ann Intern Med 1995; 122 (2): 133-41 

29. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide  and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987;  S36-42 (12): 861-6

30. Guul SJ, Os I, Jounela AJ. The efficacy and tolerability of   enalapril in a formulation with a very low dose of hydrochlorothiazide in hypertensive patients resistant to enalapril monotherapy. Am J Hypertens 1995; 8 (7): 727-31

31. Middlemost SJ, Tager R, Davis J, et al. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 1994; 73 (15): 1092-7

32. Townsend RR, Holland OB. Combination of converting enzyme  with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150 (6): 1175-83

33. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril   and hydrochlorothiazide combination therapy in hypertension . A clinical trial of factorial design. The East Germany Collaborative Trial Group. J Hypertens 1993; 11 (2): 217-21

 34. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12 (12):
861-6

35. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.  Am J Hypertens 1999; 12 (8 Pt 1): 797-805

36. Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more
effective than enalapril in reducing blood pressure and left ventricular mass: The PICXEL study. J Hypertens 2005; 23:2063–2070

37. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the Avoiding
Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial. Am J Hypertens 2004; 17:793– 801.

38.  Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.. N Engl J Med 2008;359:2417-28.

39. Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension (TV-51). Am J Hypertens 1998; 11:322–327.

40. Pepine CJ, Handberg EM, Cooper-Dehoff RM, et al., for the INVEST Investigators.
A calcium antagonist versus a noncalcium antagonist hypertension treatment strategy for patients with coronary heart disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290:2805–2816

41.   Philipp T, Smith TR, Glazer R et al. Two Multicenter, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies Evaluating the Efficacy and Tolerability of Amlodipine and Valsartan in Combination and as Monotherapy in Adult Patients with Mild to Moderate Essential Hypertension. Clin Ther. 2007;29:563-580

42. Ram CV. Antihypertensive drugs: an overview. Am J Cardiovasc Drugs 2002; 2 (2):
77-89

43. Chrysant  SG. Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. Clin Drug Invest 2008; 28 (11): 713-734

44. Bangalore S, Kamalakkannan G, Parker S, et al. Fixed combinations improve medical compliance. Ameta-analysis. Am J Med 2007; 120:713-19

45. Fadia T. Shaya, PhD, MPH; Dongyi Du, MS; Confidence M. Gbarayor; Feride Frech-Tamas, MPH;Helen Lau, MS; Matthew R. Weir, MD. Predictors of Compliance with Antihypertensive Therapy in a High-Risk Medicaid Population. J Natl Med Assoc. 2009;101:34-39

46. Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. 2008;30(8):1558-63

47. Sica DA. Fixed-dose combination antihypertensive drugs: do they have a role in rational therapy? Drugs 1994; 48 (1): 16-24

48. Black HR. Triple Fixed-Dose Combination Therapy: Back to the Past.  Hypertension 2009;54;19-22